NEW PUBLICATION: EMAS is extremely proud to announce publication of a new clinical guide on Menopause, wellbeing and health: A care pathway from the European Menopause and Andropause Society. Women’s health is increasingly recognized as a global health priority and the complications of estrogen deficiency and ageing present an enormous problem to…
Women’s health is increasingly recognized as a global health priority. Managing perimenopausal and postmenopausal health is a key issue worldwide. Therefore EMAS is making available to all short fact sheets to help women, healthcare and non healthcare professionals understand menopausal health. Read more
NEW PUBLICATION: EMAS is extremely proud to announce the EMAS 2021 Global Recommendations on Menopause in the Workplace. This will be followed by a Menopause Charter for employers and a Self-Assessment tool for employers and managers. Read more: https://emas-online.org/emas-and-menopause-in-the-workplace-2021 Menopause in the Workplace
Vulvovaginal atrophy is a chronic condition caused by estrogen deficiency which affects around 50% of postmenopausal women. EMAS has published a clinical guide on the use of both topical estrogens and non-hormonal lubricants and moisturizers so that treatment can be individualized. Read more https://www.sciencedirect.com/science/article/pii/S037851222100061X
February 11, 2020 – European Menopause and Andropause Society (EMAS) and International Gynecologic Cancer Society (IGCS) Position statement on managing the menopause after gynecological cancer Worldwide, 1.3 million new gynecological cancer cases are diagnosed each year. Treatment can result in loss of ovarian function and, in women under the age of 45, early menopause. This position…
30 September 2020 – A new clinical guide by the European Menopause and Andropause Society (EMAS) on the management of urinary incontinence in postmenopausal women is published in Maturitas. Urinary incontinence affects over 1 in 2 women aged over 60 years. The clinical guide provides evidence-based recommendations for the diagnosis and management of this common…
Online on 12 August the editorial written by Eleni Armeni, Antonio Cano, Margaret Rees and Irene Lambrinoudaki after publication of 20 year WHI follow up data concludes that that estrogen monotherapy is safe in the long-term with regard to breast cancer risk. The need to use progestogens with a better breast safety profile, such as…
EMAS published in Maturitas a position statement on the evidence about the Mediterranean Diet and menopausal health on 15 July 2020. It concludes that long-term high adherence may: reduce cardiovascular risk, maintain bone health, help to prevent cognitive decline, reduce the risk of breast cancer, reduce the risk of all-cause mortality. Click here to read…
Dyslipidemias are common and increase the risk of cardiovascular disease. The menopause transition is associated with an atherogenic lipid profile. Published in Maturitas EMAS has produced an evidence-based clinical guide evaluating the effects on the lipid profile both of menopausal hormone therapy and of non-estrogen-based treatments for menopausal symptoms. Click here to read more. Menopause…